首个专门针对清除潜伏HIV-1细胞的T细胞受体（TCR）疗法已经通过了初步临床试验。这种双特异性免疫疗法可以靶向并清除那些长期携带HIV的CD4+细胞，也就是所谓的“病毒储存库”。

MHH team aims to intervene in the autoimmune process and stop the destruction of insulin-producing beta cells in the pancreas ...

TCR can be used to identify naturally tumor-reactive T cells ... Antibodies used for flow cytometry were FITC-conjugated anti-human CD3 (RRID : AB 10893003), PE-conjugated anti-human CD4 (RRID : ...

1月2日，星汉德生物（SCG）宣布，国家药品监督管理局药品审评中心（NMPA）已批准其全新一代人乳头瘤病毒（HPV）特异性T细胞受体（TCR）工程化T ...

From the Department of Cardiology and Angiology I, University Heart Center Freiburg, Germany (D.W.) Faculty of Medicine, University of Freiburg, Germany (D.W.) K. Ley has received research funding for ...

这项“利用TCR-T细胞治疗一例晚期乙肝相关肝癌患者”的临床研究成果荣登《临床和分子肝病学》的封面论文，标志着我国TCR-T研究的重大进步 ...

The DALI tool facilitates linking TCR clonotype information to functional properties ... BioLegend), anti-CD4 (BUV395, BD Biosciences) and anti-CD3 (BUV737, BD Biosciences), anti-Ki-67 (BV786, BD ...

和T细胞受体（TCR）复合物的固定成分CD3发挥作用(CD3 X TAA) 。TCE双抗的优势在于可以通过CD3利用所有可用的T细胞，而不局限于肿瘤特异性T细胞。

“We believe that the combination of Medigene’s 3S TCR and WuXi Biologics’ CD3 mAb and bispecific platform offers the potential of a best-in-class therapeutic that precisely targets broad ...

Medigene and WuXi began a three-year research collaboration earlier this year to leverage Medigene's TCR development expertise alongside WuXi's anti-CD3 monoclonal antibody, TCE platform, and ...